Eli Lilly (LLY)
(Delayed Data from NYSE)
$952.74 USD
-1.43 (-0.15%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $950.50 -2.24 (-0.24%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Eli Lilly (LLY) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$967.87 | $1,117.00 | $610.00 | 1.44% |
Price Target
Based on short-term price targets offered by 23 analysts, the average price target for Eli Lilly comes to $967.87. The forecasts range from a low of $610.00 to a high of $1,117.00. The average price target represents an increase of 1.44% from the last closing price of $954.17.
Analyst Price Targets (23)
Broker Rating
Eli Lilly currently has an average brokerage recommendation (ABR) of 1.11 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 23 brokerage firms. The current ABR compares to an ABR of 1.20 a month ago based on 22 recommendations.
Of the 23 recommendations deriving the current ABR, 21 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 91.3% and 4.35% of all recommendations. A month ago, Strong Buy made up 86.36%, while Buy represented 4.55%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/LLY.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 21 | 21 | 19 | 19 | 19 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.11 | 1.11 | 1.20 | 1.20 | 1.20 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/15/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/14/2024 | Daiwa America | Narumi Nakagiri | Strong Buy | Strong Buy |
8/9/2024 | BMO Capital Markets | Evan Seigerman | Strong Buy | Strong Buy |
8/8/2024 | Truist Securities | Srikripa Devarakonda | Strong Buy | Strong Buy |
8/5/2024 | Guggenheim Securities | Seamus Fernandez | Strong Buy | Strong Buy |
7/25/2024 | SVB Securities | David Risinger | Strong Buy | Strong Buy |
7/24/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
7/12/2024 | UBS | Trung Huynh | Strong Buy | Strong Buy |
7/11/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/2/2024 | Berenberg Bank | Kerry Holford | Strong Buy | Strong Buy |
7/1/2024 | Cantor Fitzgerald & Co | Louise Chen | Strong Buy | Strong Buy |
5/30/2024 | Wells Fargo Securities | Mohit Bansal | Strong Buy | Strong Buy |
5/16/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/14/2024 | Argus Research Corp. | David A Toung | Strong Buy | Strong Buy |
5/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/30/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/11/2024 | Goldman Sachs | Chris Shibutani | Hold | Hold |
4/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Steve M Scala | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.11 |
ABR (Last week) | 1.11 |
# of Recs in ABR | 23 |
Average Target Price | $984.39 |
LT Growth Rate | 20.00% |
Industry | Large Cap Pharmaceuticals |
Industry Rank by ABR | 93 of 253 |
Current Quarter EPS Est: | 4.35 |